← Eichor
Study identifier: NCT05985850 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Evaluating Tetrahydrocannabinol as an Adjunct to Opioid Agonist Therapy

Condition: Opioid Use Disorder · Methadone · Cannabis  ·  Sponsor: BC Centre on Substance Use

PhasePhase 2
Planned participants24
Who can joinAll sexes, 25 Years to no upper limit
Healthy volunteersNo

About this study

This pilot study will evaluate the feasibility and safety of using 1:1 tetrahydrocannabinol (THC):Cannabidiol (CBD) cannabis oil as an adjunct therapy to methadone-based Opioid Agonist Therapy (OAT) for individuals with opioid use disorder (OUD) in a community setting.

This description comes directly from the study's public registry record.

Talk to the study team

Josie Kanu, BSc  ·  6045001102  ·  josie.kanu@bccsu.ubc.ca

Always discuss trial participation with your own doctor first.

Locations (1)

Rapid Access Addiction Clinic (RAAC), St. Paul's HospitalVancouver, British Columbia, CanadaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05985850